Search
Now showing items 1-3 of 3
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
BACKGROUND:The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate ...
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
(2020-08)
The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to ...
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
(AMER ASSOC CANCER RESEARCH, 2021-10-01)
Outcomes for patients with melanoma have improved over the past decade as a result of the development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and ...